Iduronate-2-sulfatase enzyme replacement therapy
TKT024
Phase 3 mab completed
Quick answer
Iduronate-2-sulfatase enzyme replacement therapy for Mucopolysaccharidosis II is a Phase 3 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Mucopolysaccharidosis II
- Phase
- Phase 3
- Modality
- mab
- Status
- completed